|
1）Zeilhofer HU, Caló G. Nociceptin/Orphanin FQ and its receptor-potential targets for pain therapy? J Pharmacol Exp Ther. 2003; 306: 423-9
|
|
|
|
2）Lambert DG. The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential. Nat Rev Drug Discov. 2008; 7: 694-710
|
|
|
|
|
|
3）Okuda-Ashitaka E, Minami T, Tachibana S, et al. Nocistatin, a peptide that blocks nociceptin action in pain transmission. Nature. 1998; 392: 286-9
|
|
|
|
|
|
4）Ito S, Okuda-Ashitaka E, Imanishi T, et al. Central roles of nociceptin/orphanin FQ and nocistatin: allodynia as a model of neural plasticity [In Process Citation]. Prog Brain Res. 2000; 129: 205-18
|
|
|
|
|
|
5）Mustazza C, Bastanizo G. Development of nociceptin receptor (NOP) agonists and antagonists. Med Res Rev. 2011; 31: 605-48
|
|
|
|
|
|
6）Okuda-Ashitaka E, Tachibana S, Houtani T, et al. Identification and characterization of an endogenous ligand for opioid receptor homologue ROR-C: its involvement in allodynic response to innocuous stimulus. Mol Brain Res. 1996; 43: 96-104
|
|
|
|
|
|
7）Xu L, Okuda-Ashitaka E, Matsumura S, et al. Signal pathways coupled to activation of neuronal nitric oxide synthase in the spinal cord by nociceptin/orphanin FQ. Neuropharmacology 2007; 52: 1318-25
|
|
|
|
|
|
8）Okuda-Ashitaka E, Minami T, Tsubouchi S, et al. Identification of NIPSNAP1 as a nocistatin-interacting protein involving pain transmission. J Biol Chem. 2012; 287: 10403-13
|
|
|
|
|
|
9）Chen Y-L, Li AH, Yen T-H, et al. Nocistatin and nocicepin exert opposite effects on the excitability of central amygdala nucleus-periaqeductal gray projection neurons. Mol Cell Neurosci. 2008; 40: 76-88
|
|
|
|
|
|
10）Schoeber JP, Topala CN, Lee KP, et al. Identification of NIPSNAP1 as a novel auxiliary protein inhibiting TRPV6 activity. Eur J Pharmacol. 2007; 152: 549-55
|
|
|
|
|
|
11）Nakano H, Minami T, Abe K, et al. Effect of intrathecal nocistatin on the formalin-induced pain in mice versus that of nociceptin/orphanin FQ. J Pharmacol Exp Ther. 2000; 292: 331-6
|
|
|
|
|
|
12）Ahmadi S, Muth-Selbach U, Lauterbach A, et al. Facilitation of spinal NMDA receptor currents by spillover of synaptically release glycine. Science. 2003; 300: 2094-7
|
|
|
|
|
|
13）Pan ZZ, Hirakawa N, Fields HL. A cellular mechanism for the bidirectional pain-modulating actions of orphanin FQ/nociceptin. Neuron. 2000; 26: 515-22
|
|
|
|
|
|
14）Norton CS, Neal CR, Kumar S, et al. Nociceptin/orphanin FQ and opioid receptor-like receptor mRNA expression in dopamine sysytems. J Comp Neuro. 2002; 444: 358-68
|
|
|
|
|
|
15）Matri M, Mela F, Veronesi C, et al. Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigro-striatal dopaminergic transmission and motor behavior. J Neurosci. 2004; 24: 6659-66
|
|
|
|
|
|
16）Marti M, Guerrini R, Beani L, et al. Nociceptin/orphanin FQ receptors modulate glutamate extracellular levels in the substantia nigra pars reticulata. A microdialysis study in the awake freely moving rat. Neuroscience. 2002; 112: 153-60
|
|
|
|
|
|
17）Marti M, Trapella C, Viaro R, et al. The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway. J Neurosci. 2007; 27: 1297-307
|
|
|
|
|
|
18）Brown JM, Gouty S, Iyer V, et al. Differential protection against MPTP or methamphetamine toxicity in dopamine neurons by deletion of ppN/OFQ expression. J Neurochem. 2006; 98: 495-505
|
|
|
|
|
|
19）Marti M, Mela F, Fantin M, et al. Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinsonʼs disease. J Neurosci. 2005; 25: 9591-601
|
|
|
|
|
|
20）Oilanas MC, Dedoni S, Bol M, et al. Activation of nociceptin/orphanin FQ-NOP receptor system inhibits tyrosine hydroxylase phosphorylation, dopamine synthesis, and dopamine D1 receptor signaling in rat nucleus accumbens and dorsal striatum. J Neurochem. 2008; 107: 544-56
|
|
|
|
|
|
21）Marti M, Rodi D, Li Q, et al. Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias. J Neurosci. 2012; 32: 16106-19
|
|
|
|
|